Compare STRA & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRA | DMRA |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 1996 | 2020 |
| Metric | STRA | DMRA |
|---|---|---|
| Price | $80.45 | $21.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $87.00 | $43.00 |
| AVG Volume (30 Days) | 206.0K | ★ 310.9K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | ★ 15.85 | N/A |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $997,137,000.00 | N/A |
| Revenue This Year | $4.71 | N/A |
| Revenue Next Year | $4.67 | N/A |
| P/E Ratio | $55.08 | ★ N/A |
| Revenue Growth | ★ 57.23 | N/A |
| 52 Week Low | $69.70 | $16.50 |
| 52 Week High | $88.50 | $28.76 |
| Indicator | STRA | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 54.14 | 37.24 |
| Support Level | $78.96 | N/A |
| Resistance Level | $84.09 | $27.70 |
| Average True Range (ATR) | 2.00 | 1.89 |
| MACD | 0.31 | -0.37 |
| Stochastic Oscillator | 66.33 | 32.95 |
Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.